Abuse-deterrent formulations: Part 2: Commercial products and proprietary technologies

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 3, 2015, Pages 305-323

  Mastropietro, David J ^a   Omidian, Hossein ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Abuse deterrent; Misuse; Nonmedical use; Opioids; Prescription drug abuse; Tamper resistant

Indexed keywords

ATROPINE PLUS DIPHENOXYLATE; BUPRENORPHINE PLUS NALOXONE; FLUNITRAZEPAM; HOMATROPINE METHYL BROMIDE PLUS HYDROCODONE BITARTRATE; HYDROMORPHONE; LISDEXAMFETAMINE; MORPHINE SULFATE PLUS NALTREXONE; NALOXONE PLUS OXYCODONE; NALOXONE PLUS PENTAZOCINE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; TAPENTADOL; DRUG DOSAGE FORM; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ABUSE DETERRENT FORMULATION; CONTROLLED RELEASE FORMULATION; DRUG ABUSE; DRUG CAPSULE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; PATENT; PHARMACEUTICAL ENGINEERING; PRESCRIPTION; REVIEW; TABLET FORMULATION; DRUG DOSAGE FORM; MEDICINAL CHEMISTRY; OPIOID-RELATED DISORDERS; PAIN;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUGS;

EID: 84921482757     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.970175     Document Type: Review

References (108)

1. Manchikanti L, Atluri S, Candido KD, et al. Zohydro approval by Food and Drug Administration: controversial or frightening? Pain Physician 2014;17(4):E437-E50
2. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351-8
3. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013;14(10):1122-30
4. Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System. Abuse deterrent formulations - Updated RADARS® system data. RADARS System Third Quarter Newsletter 2013;8(3)
5. U.S. Food and Drug Administration. FDA approves abuse-deterrent labeling for reformulated OxyContin. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm [Last accessed 31 March 2014]
6. Food and Drug Administration. (Draft) Guidance for industry, abuse-deterrent opioids-evaluation and labeling. 2013. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf [Last accessed 24 March 2014] •• Outline for development and labeling of abuse-deterrent formulation (ADF).
7. Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013;130(1-3):13-23
8. Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc 2012;87(7):683-94 •• Review of ADFs.
9. Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend 2014;138:1-6
10. Lourenco LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv 2013;10(2):229-40 •• Review on ADFs.
11. Covidien. FDA approves Mallinckrodt's EXALGO® (hydromorphone HCl) extended-release tablets 32 mg (CII) for opioid-tolerant patients with moderate-to-severe chronic pain. 2012. Available from: http://www.covidien.com/investor [Last accessed 30 March 2014]
12. DuPont RL, Lande SD. Impact of drug formulation: the impact of abuse deterrent formulation on the incidence of abuse and diversion of OROS methylphenidate. Drug Alcohol Depend 2006;83(Suppl 1):S83-9
13. Hee Han D. Polyethylene oxide tapentadol ER formulation proves crush-resistant. Monthly Prescribing Reference (MPR), PAINWeek 2012 Neuropathic Pain 2012. Available from: http://www.empr.com/polyethylene-oxide-tapentadol-er-formulation-proves-crush-resistant/article/257976/ [Last accessed 31 March 2014]
14. Pergolizzi J, Galia E, Williams Y, et al. Tamper-resistant properties of tapentadol extended-release tablets [poster]. Presented at the 2013 American Academy of Pain Medicine (AAPM) Annual Meeting. 2013. Available from: http://www.painmed.org/2013posters/abstract-125/ [[Last accessed 31 March 2014]
15. Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T 2012;37(7):412-18
16. U.S. Food and Drug Administration. FDA statement: original opana ER relisting determination. 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm [Last accessed 30 March 2014]
17. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005;6(10):662-72
18. Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag 2005;1(2):77-82
19. U.S. Food and Drug Administration. FDA approves new formulation for OxyContin®. 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm [Last accessed 31 March 2014]
20. Purdue Pharma L.P. Purdue meeting background materials, NDA 22-272 reformulated OxyContin®, joint meeting of the anesthetic and life support drugs advisory committee and drug safety and risk management advisory committee. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4356b1-02-Purdue.pdf [Last accessed 31 March 2014]
21. Mallinckrodt Pharmaceuticals. Xartmis Xr [Product homepage]. 2014. Available from: http://www.xartemisxr.com/ [Last accessed 17 April 2014]
22. Mallinckrodt Pharmaceuticals. Mallinckrodt opioid safe use initiatives : oxycodone and Mallinckrodt's abuse-deterrent technology [Presentation]. 2014. Available from: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM1OTA4fENoaWxkSUQ9MjI0MDAzfFR5cGU9MQ==&t=1 [Last accessed 6 June 2014]
23. Singla N. A randomized, double-blind, placebo-controlled, phase 3 study of the safety and analgesic efficacy of MNK-795 controlled-release oxycodone/acetaminophen tablets (CR OC/APAP) in an acute pain model [Oral Presentation]. Pain Week 2013. Available from: http://www.lotuscr.com/lotus-pdf/Mallinckrodt-MNK795-PainWeek2013-OralPresentation-101.pdf [Last accessed 17 April 2014]
24. EMBEDA®[package insert]. Pfizer; New York City, NY: 2013
25. Alpharma Pharmaceuticals LLC. EMBEDA®extended release capsules: joint anesthetic and life support drugs (ALSDAC) and drug safety and risk management (DSaRM) advisory committee briefing document. 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM230111.pdf [Last accessed 25 June 2014]
26. Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol 2012;52(5):747-56
27. Pfizer, Inc. Embeda®: important information for patients and prescribers. Available from: http://embeda.com/ [Last accessed 20 Feb 2014]
28. Pfizer, Inc. Pfizer receives FDA approval for a prior approval supplement for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended release capsules CII. 2013. Available from: http://www.pfizer.com/news/press-release/press-release-archive-detail/pfizer-receives-fda-approval-for-a-prior-approval-supplement-for-embeda-morphine-sulfate-and-naltrexone-hydrochloride-extended-release-capsules-cii [Last accessed 20 July 2014]
29. Mehta AM. inventor. Abuse-resistant oral dosage forms and method of use thereof. US8182836; 2012
30. Mehta AM. inventor. Abuse-resistant oral dosage forms and method of use thereof. US8425933; 2013
31. Elite Pharmaceuticals, Inc. Recent Press Releases. 2014. Available from: http://www.elitepharma.com/ [Last accessed 29 March 2014]
32. Reckitt Benckiser Pharmaceuticals, Inc. SUBOXONE film, key benefits. 2013. Available from: http://www.suboxone.com/hcp/about-suboxone/key-benefits.aspx [Last accessed 20 February 2014]
33. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987;102(4):426-9
34. Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm 2013;39(5):611-24
35. Purdue Pharma L.P. FDA accepts for review Purdue Pharma's new drug application for Targiniq™ ER (oxycodone HCl/naloxone HCL controlled-release) tablets CII. 2013. Available from: [http://www.purduepharma.com/news-media/2013/11/] [Last accessed 22 July 2014]
36. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23(4):419-27
37. Dew RE, Kollins SH. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother 2010;11(17):2907-13
38. Mehra A, Sarkar S, Basu D. Lomotil (diphenoxylate) dependence in India. Indian J Psychol Med 2013;35(3):248-50
39. Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 1997;17(3 Suppl 2):1S-57S
40. Martinez A, Rougeot O, Yaguchi Y. inventors. Pharmaceutical composition for oral administration intended to prevent misue. US0280326; 2013
41. Tussigon®[package insert]. Monarch Pharmaceuticals, Inc; Bristol, TN: 2011
42. Acura Pharmaceuticals, Inc. Acurox® with niacin tablets 2014. Available from: http://acurapharm.com/products/acurox-tablets/ [Last accessed 31 March 2014]
43. Acura Pharmaceuticals, Inc. Study AP-ADF-107, a phase II single-center, randomized, double-blind study in fasted and non-fasted healthy volunteers to evaluate the dose response for flushing and safety and tolerability of escalating doses of niacin. 2011. Available from: http://acurapharm.com/products/acurox-tablets/study-ap-adf-107/ [Last accessed 19 February 2014]
44. Acura Pharmaceuticals, Inc. Nexafed [Product Website]. 2012. Available from: http://www.nexafed.com/ [Last accessed 31 March 2014]
45. Brzeczko AW, Leech R, Stark JG. The advent of a new pseudoephedrine product to combat methamphetamine abuse. Am J Drug Alcohol Abuse 2013;39(5):284-90
46. Westport Pharmaceuticals. Zephrex-D nasal decongestant unique formulation. 2012. Available from: http://zephrex-d.com/unique-formulation/ [Last accessed 31 March 2014]
47. Marcenyac G, Alfonso M, Gehrlein L, et al. inventors. Disposal system for transdermal dosage form. US0262284; 2008
48. Goldberg AP. inventor. Transdermal delivery form disposal systems and methods. US12048771; 2008
49. Tavares L, Reidenberg BE, Sackler R, et al. inventors. Abuse resistant opioid containing transdermal systems. US0241218; 2004
50. Cai B, Engqvist H, Bredenberg S. Evaluation of the resistance of a geopolymer-based drug delivery system to tampering. Int J Pharm 2014;465(1-2):169-74
51. Capsugel. ABUSOLVE Abuse Deterrent Formulations. 2014. Available from: http://capsugel.com/en/products-services/services/abusolve/ [Last accessed 3 March 2014]
52. Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manage 2010;39(4):712-20
53. Andersen C, Lindhardt K, Oevergaard JM, inventors. Formulations and methods for the controlled release of active drug substances. US8563038; 2013
54. Tygesen PH, Lindhardt K, Olsen MR, et al. inventors. Abuse deterrent pharmaceutical compositions for controlled release. US0010873; 2014
55. Acura Pharmaceuticals, Inc. AVERSION® Technology. 2014. Available from: http://acurapharm.com/platforms/aversion-technology/ [Last accessed 26 March 2014]
56. Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Acura Pharmaceuticals, Inc., assignee. Methods and compositions for deterring abuse of opioid containing dosage forms. US7201920; 2007
57. Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Acura Pharmaceuticals, Inc., assignee. Methods and compositions for deterring abuse of opioid containing dosage forms. US7476402; 2009
58. Kumar V, Dixon D, Tewari D, Wadgaonkar DB. inventors. Extended release opioid abuse deterrent compositions and methods of making same. US8101630; 2012
59. Collegium Pharmaceutical. DETERx technology introduction. 2013. Available from: http://www.collegiumpharma.com/technology-introduction [Last accessed 4 December 2013]
60. Hirsh J, Kibanov AM, Swager TM, et al. inventors. Abuse-deterrent pharmaceutical compositions of opiods and other drugs. US7399488; 2008
61. Hirsh J, Fleming A, Rariy R, Klibanov AM. inventors. Abuse-deterrent drug formulations. US7771707; 2010
62. Hirsh J, Fleming A, Rariy R, Kilbanov A. inventors. Abuse-deterrent drug formulations. US8449909; 2013
63. Collegium Pharmaceutical. Collegium Pharmaceutical, Inc. Announces issuance of patent covering oxycodone DETERx®, an abuse-deterrent, extended-release opioid product. 2013. Available from: http://www.collegiumpharma.com/press-releases [Last accessed 25 March 2013]
64. Bartholomaus J, Ashworth J, Stahlberg H-J, et al. Innovative formulation technology protecting intended drug action. Drug Dev Deliv 2012;12(8):69-75
65. Bartholomaus J, Kugelmann H, Arkenau-Maric E. inventors; Abuse-proofed dosage form. US8114383; 2012
66. Bartholomaus J, Schwier S, Brett M, et al. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv 2013;13(8):76-81
67. Intellipharmaceutics International. Technology portfolio; products. 2014. Available from: http://www.intellipharmaceutics.com/ [Last accessed 27 March 2014]
68. Odidi I, Odidi A. inventors. Pharmaceutical composition having reduced abuse potential. US0232887; 2009
69. Ethypharm. Proprietary technologies: LOCKTAB®, protected by three patent families. Available from: http://www.ethypharm.com/drug-technologies/proprietary-technologies.html [Last accessed 2014 20 July]
70. Trichard L. New trends in drug abuse deterrence: Locktab formulations to address drug misuse and abuse. 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Malta; 2010
71. Cailly-Dufestel V, Herry C, Bacon J, Oury P. inventors. Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion. US8501160; 2013
72. Tris Pharma, Inc. ABUSE RESISTANCE: nobuse™. 2014. Available from: http://www.trispharma.com/technologies-nobuse.php [Last accessed 27 March 2014]
73. Mehta K, Tu Y-H, Chaudhuri A, Perumal A. inventors. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings. WO119231; 2013
74. Di-Filippo P. Abuse-deterrent formulations: developers try to head off an epidemic. Contract Pharma Magazine 2013
75. DURECT Corp. ORADUR: oral Delivery Technology. 2012. Available from: http://www.durect.com/pdf/Durect-Oradur-Brochure-2012.pdf [Last accessed 26 March 2014]
76. Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8420120; 2013
77. Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8354124; 2013
78. Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8147870; 2012
79. Yum SI, Schoenhard G, Tipton AJ, Gibson JW. inventors. Oral drug delivery system. US8153152; 2012
80. Yum SI, Schoenhard G, Tipton AJ, Gibson JW. inventors. Oral drug delivery system. US8168217; 2012
81. Yum SI, Schoenhard G, Tipton AJ, inventors. Oral drug delivery system. US8133507; 2012
82. Pain Therapeutics, Inc. NDA 22-324 Remoxy XRT, advisory committee briefing materials for the anesthetic life support drugs advisory committee meeting of November 13, 2008. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf [Last accessed 17 March 2011]
83. Pain Therapeutics, Inc. FDA complete response letter received for REMOXY. 2011. Available from: http://investor.paintrials.com/releasedetail.cfm?ReleaseID=587311 [Last accessed 20 March 2011]
84. DURECT Corp. ORADUR technology. 2014. Available from: http://www.durect.com/wt/durect/page-name/oradur [Last accessed 26 March 2014]
85. Haswani D, Nagel JC, Moe D, Hamed E. OraGuard(TM): a tampering-deterrent & alcohol-resistant extended-release technology. Drug Dev Deliv 2012;12(8):42-50
86. Habib W, Hamed E, Vega Zepeda MA. inventors. Abuse resistant drug formulation. US8445018; 2013
87. Babul N. inventor. Multimodal abuse resistant and extended release opioid formulations. US0249045; 2010
88. Babul N. inventor. Extended release oral pharmaceutical compositions of 3-hydroxy-N-methylmorphinan and method of use. US0065221; 2012
89. Relmada Therapeutics. Development pipeline. 2013. Available from: www.relmada.com [Last accessed 2014 27 March 2014]
90. Atlantic Pharmaceuticals, Inc. Abuse deterrebt oral delivery system (SMART/Script). 2013. Available from: http://www.atlanticpharma.com/technology.html [Last accessed 27 February 2014]
91. Soscia AE, Peng Y, Sun Y, inventors. Dosage forms for tamper prone therapeutic agents. US8349362; 2013
92. Soscia AE, Peng Y, Sun Y, inventors. Dosage forms for tamper prone therapeutic agents. US8187636; 2012
93. Shukla AJ, Soscia AE, Peng Y, inventors. Dosage forms for tamper prone therapeutic agents. US8507001; 2013
94. Vachon M, Rudnic EM. inventors. Technology for preventing abuse of solid dosage forms. US0321716; 2012
95. Flamel Technologies SA. Trigger Lock drug delivery platform. 2014. Available from: http://www.flamel.com/wp-content/uploads/2013/12/Flamel-Technologies-Trigger-Lock-Drug-Delivery-Platform.pdf [Last accessed 26 March 2014]
96. Guimberteau F, Dargelas F. inventors. Anti-misuse microparticulate oral pharmaceutical form. US8445023; 2013
97. Shah MS, Difalco RJ. inventors. Abuse resistant drugs, method of use and method of making. US7955619; 2011
98. Vinson RK. Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility. Clin Drug Investig 2012;32(7):487-95
99. Betancourt AO, Gosselin PM, Vinson RK. New immediate release formulation for deterring abuse of methadone. Pharm Dev Technol 2013;18(2):535-43
100. Vinson R, Gosseling P, Betancourt AO. inventors. Narcotic drug formulations with decreased abuse potential. US8460640; 2013
101. Rahmouni M, Ferrada A, Soulhi F, et al. inventors. Misuse preventative, controlled release formulation. US0344142; 2013
102. Rahmouni M, Ferrada A, Soulhi F, et al. inventors. Misuse preventative, controlled release formulation. US8486448; 2013
103. Rahmouni M, Gervais S, Sant V, et al. inventors. Misuse preventative, controlled release formulation. US8486449; 2013
104. Rahmouni M, Gervais S, Sant V, et al. inventors. Misuse preventative, controlled release formulation. US0004191; 2014
105. Gervais S, Smith D, Contamin P, inventors. Sustained drug release composition. US0033537; 2011
106. Purdue Pharma L.P. FDA grants priority review designation for Purdue Pharma's once-daily hydrocodone bitartrate extended-release tablets formulated with abuse-deterrent properties. 2014. Available from: http://www.purduepharma.com/news-media/2014/07/[Last accessed 22 July 2014]
107. Brzeczko AW, Hollenbeck RG. inventors. Methods and compositions for self-regulated release of active pharmacetical ingredient. US0155388; 2014
108. FDA center for drug evaluation and research, Division of anethesia, analgesia, and addition products. Nucynta ER: summary review for regulatory action NDA 200533. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/200533Orig1s000SumR.pdf [Last accessed 6 March 2014]